Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LyRICX first-line chemotherapy comparison in metastatic esophagogastric adenocarcinoma
NL-OMON54618Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome, carboplatin, oxaliplatin, fluorouracil, capecitabine and 2 more in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Progression-free survival and Neurotoxicity. Started Sep 2019; status: recruiting.
02
Drugs
irinotecan liposomecarboplatinoxaliplatinfluorouracilcapecitabine
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON54618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54618.